A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Synthesis, Ga-68 labeling and preliminary evaluation of DOTA peptide binding vascular adhesion protein-1: a potential PET imaging agent for diagnosing osteomyelitis
Tekijät: Ujula T, Salomaki S, Virsu P, Lankinen P, Makinen TJ, Autio A, Yegutkin GG, Knuuti J, Jalkanen S, Roivainen A
Kustantaja: ELSEVIER SCIENCE INC
Julkaisuvuosi: 2009
Journal: Nuclear Medicine and Biology
Tietokannassa oleva lehden nimi: NUCLEAR MEDICINE AND BIOLOGY
Lehden akronyymi: NUCL MED BIOL
Vuosikerta: 36
Numero: 6
Aloitussivu: 631
Lopetussivu: 641
Sivujen määrä: 11
ISSN: 0969-8051
DOI: https://doi.org/10.1016/j.nucmedbio.2009.04.008
Tiivistelmä
Introduction: Vascular adhesion protein-1 (VAP-1) is an infection/inflammation-inducible endothelial glycoprotein. Based on Our previous studies, the most VAP-1-selective peptide (VAP-P1) was 1,4,7,10-tetraazacyclododecane-N',N '',N'",N ''''-tetraacetic acid (DOTA)-conjugated, (68)gallium (Ga-68)-labeled (named [Ga-68]DOTAVAP-P1) and evaluated preliminarily.Methods. Targeting was evaluated by using VAP-1-transfected cells. Biodistribution of [Ga-68]DOTAVAP-P1 was studied by positron emission tomography imaging of healthy rats and rats with bone inflammation caused by Staphylococcus aureus infection. Uptake of [Ga-68] DOTAVAP-P1 in osteomyelitis was compared with negative control peptide and competition with an excess of unlabeled DOTAVAP-P1.Results: [Ga-68]DOTAVAP-P1 bound more efficiently to VAP-1-transfected cells than to controls. In rats, [Ga-68]DOTAVAP-P1 cleared rapidly front blood circulation, excreted quickly in urine and showed an in vivo half-life of 26 +/- 2.3 min. Imaging of osteomyelitis demonstrated modest target-to-background ratio. Studies with the negative control peptide and competitors revealed a significantly lower uptake at the infection site compared to [Ga-68]DOTAVAP-P1.Conclusions: The results represent a proof-of-concept that infection-induced VAP-1 can be targeted by [Ga-68]DOTA peptide. [Ga-68] DOTAVAP-P1 is just the first candidate peptide and an essential opening for developing VAP-1-specific imaging agents. (C) 2009 Elsevier Inc. All rights reserved.
Introduction: Vascular adhesion protein-1 (VAP-1) is an infection/inflammation-inducible endothelial glycoprotein. Based on Our previous studies, the most VAP-1-selective peptide (VAP-P1) was 1,4,7,10-tetraazacyclododecane-N',N '',N'",N ''''-tetraacetic acid (DOTA)-conjugated, (68)gallium (Ga-68)-labeled (named [Ga-68]DOTAVAP-P1) and evaluated preliminarily.Methods. Targeting was evaluated by using VAP-1-transfected cells. Biodistribution of [Ga-68]DOTAVAP-P1 was studied by positron emission tomography imaging of healthy rats and rats with bone inflammation caused by Staphylococcus aureus infection. Uptake of [Ga-68] DOTAVAP-P1 in osteomyelitis was compared with negative control peptide and competition with an excess of unlabeled DOTAVAP-P1.Results: [Ga-68]DOTAVAP-P1 bound more efficiently to VAP-1-transfected cells than to controls. In rats, [Ga-68]DOTAVAP-P1 cleared rapidly front blood circulation, excreted quickly in urine and showed an in vivo half-life of 26 +/- 2.3 min. Imaging of osteomyelitis demonstrated modest target-to-background ratio. Studies with the negative control peptide and competitors revealed a significantly lower uptake at the infection site compared to [Ga-68]DOTAVAP-P1.Conclusions: The results represent a proof-of-concept that infection-induced VAP-1 can be targeted by [Ga-68]DOTA peptide. [Ga-68] DOTAVAP-P1 is just the first candidate peptide and an essential opening for developing VAP-1-specific imaging agents. (C) 2009 Elsevier Inc. All rights reserved.
Turun yliopiston Tutkimustietojärjestelmän portaali